The Serum Institute of India (SII) will invest GBP 240 million in the UK to expand its vaccine business and set up a new sales office creating a large number of jobs.
This is a part of plans for GBP one billion pound India-UK Enhanced Trade Partnership creating around 6,500 jobs in Britain.
The vaccine manufacturer is among a list of nearly 20 Indian companies across sectors such as healthcare, biotech and software services to announce significant investment plans in the UK.
SII has started Phase-1 trials in the UK of a nasal vaccine against coronavirus. Serum’s investment will support clinical trials, research and development and possibly manufacturing of vaccines.
In the field of healthcare, another Indian investment highlight includes GBP 59 million by biotech firm Global Gene Corp over the next five years.
It will create 110 highly skilled jobs in the UK, mostly based in the R&D centre at Wellcome Genome Campus in Cambridge, which is the site of the Human Genome Project.